Namandjé N. Bumpus is an American pharmacologist who had served as the Principal Deputy Commissioner and Acting Chief Scientist of the Food and Drug Administration.

[3] She was previously director of the department of pharmacology and molecular sciences at Johns Hopkins University School of Medicine, where she holds the E.K.

[8] She became interested in chemistry at a young age, even writing to the American Chemical Society while still in elementary school to ask about the kind of careers chemists can have.

[10] She enjoyed the experience so much that she decided to return to the University of Michigan after graduating from Occidental College in order to pursue a PhD in pharmacology.

[8] After graduating, she accepted a postdoctoral fellowship at the Scripps Research Institute in La Jolla, California, where she worked under the guidance of Dr. Eric F. Johnson to study the regulation of CYP4A and CYP4F genes in mice.

[5] In July 2018, she was named as Associate Dean for Basic Research at Johns Hopkins University School of Medicine.

[2] She has been strongly involved with the American Society for Pharmacology and Experimental Therapeutics (ASPET), where she served as secretary and treasurer.

Bumpus and her team identified which kinases do this and found that the enzymes responsible varied by cell type, so administration route (e.g. orally or topically) could affect how effectively the drug is processed.

[13] She also studies antivirals that work through mechanisms other than reverse transcriptase inhibition such as the HIV entry inhibitor maraviroc; she found that genetic variants of CYP3A genes could impact its clearance.

[13] Bumpus' lab also found that cytochrome P450 enzymes convert the anti-epileptic valproic acid into byproducts (metabolites) that activate AMPK; they showed that this could reverse the obesity-related problems of fatty liver disease and high blood sugar in mouse models.